Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Public ClinicalTrials.gov record NCT01760655. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies
Study identification
- NCT ID
- NCT01760655
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Enrollment
- 62 participants
Conditions and interventions
Conditions
- Acute Myeloid Leukemia With FLT3/ITD Mutation
- Acute Myeloid Leukemia With Gene Mutations
- Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM
- Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214
- Aplastic Anemia
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Chronic Myelomonocytic Leukemia
- Follicular Lymphoma
- Hodgkin Lymphoma
- Myelodysplastic Syndrome
- Myelofibrosis
- Myeloid Leukemia
- Non-Hodgkin Lymphoma
- Plasma Cell Myeloma
- Polycythemia Vera
- Recurrent Adult Acute Myeloid Leukemia
- Recurrent Childhood Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia
- Therapy-Related Acute Myeloid Leukemia
Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation Procedure
- Busulfan Drug
- Cyclophosphamide Drug
- Fludarabine phosphate Drug
- Laboratory Biomarker Analysis Other
- Mycophenolate Mofetil Drug
- Peripheral Blood Stem Cell Transplantation Procedure
- Tacrolimus Drug
- Therapeutic Allogeneic Lymphocytes Biological
- Total-Body Irradiation Radiation
Procedure · Drug · Other + 2 more
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 23, 2012
- Primary completion
- Apr 14, 2022
- Completion
- Dec 4, 2022
- Last update posted
- Oct 29, 2025
2012 – 2022
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01760655, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 29, 2025 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01760655 live on ClinicalTrials.gov.